C
ryptococcus neoformans is an opportunistic fungal pathogen that is endemic to many regions of the globe and is a leading cause of meningoencephalitis among immunocompromised individuals. Additionally, this fungus causes infection among seemingly immunocompetent persons (16) , supporting its evolution to a primary human pathogen capable of initiating infection in seemingly immunocompetent people. C. neoformans cells are broadly subdivided into one of five serotype categories based on genetic properties and surface antigens: serotypes A (C. neoformans var. grubii), B (C. gattii), C (C. gattii), D (C. neoformans var. neoformans), and AD (the hybrid serotype). The majority of clinical isolates are serotype A. Infection is initiated when desiccated yeast cells or basidiospores are inhaled into the lungs, although the mechanisms of yeast cell survival and dissemination following inhalation remain incompletely understood. C. neoformans has been shown to be phagocytosed by alveolar macrophages (AMs), to proliferate intracellularly (15) , and to undergo a phagosome extrusion event in which immune cells remain intact (3, 39) . Furthermore, the capsule surrounding C. neoformans cells, an important virulence property of the yeast, has been shown to be protective against oxidative stresses (63) , which play a critical role in the ability of the host to kill invading C. neoformans cells (2, 5) .
Prior to encountering professional phagocytes in the lung, the fungal infectious propagule must interact with surfactant proteins (SPs), which have important functions during innate immune responses. Specifically, surfactant protein A (SP-A) and SP-D have been shown to opsonize and enhance the clearance of a number of microorganisms and allergens (14, 18, 23, 36, 43, 49, 50, 52) and thereby characteristically have protective functions in the lung. The roles of surfactant proteins during fungal infections remain unclear, as a number of studies have reported conflicting results, and few investigations have been performed to evaluate the role of SPs in response to C. neoformans infection in vivo. For example, Schelenz et al. have shown that SP-A binds to C. neoformans cells but does not enhance phagocytosis by macrophages (53) ; furthermore, we have demonstrated that SP-A does not play a significant role during C. neoformans infection in vivo (19) . Moreover, SP-D has also been shown to bind and aggregate C. neoformans cells in vitro (58) . An underlying variable likely affecting these results is the use of various C. neoformans strains in different studies. In addition, whether the yeast or basidiospore form of the fungus constitutes the infectious propagule remains unknown; however, despite variability in the size and the shape of basidiospores, together with differences in the associated immune responses, a rapid change to the yeast form is observed in the host (20, 60) . Thus, we focused on the role played by SPs in response to the yeast form of serotype A, the most common clinical isolate, and consider the results presented here to be relevant to responses that occur during initial C. neoformans infection.
We have previously demonstrated that preopsonization with SP-D enhances phagocytosis of the acapsular cap59⌬ mutant strain by macrophages and leads to the increased survival of both wild-type (H99) and cap59⌬ cells (17) in vitro. Interestingly, those results are inconsistent with the paradigm that SP-D plays a hostprotective role during innate immune responses, thus changing our hypothesized mechanism for the role of SP-D during C. neoformans infection. Consequently, the present study was under-taken to extend those studies by evaluating the role of SP-D during C. neoformans infection in vivo, utilizing a mouse model of C. neoformans infection. The data presented herein suggest that SP-D does indeed function to protect C. neoformans cells during infection and is exploited by the yeast cells to subvert host pulmonary immune mechanisms. To elucidate the mechanism(s) by which SP-D protects C. neoformans cells, we examined the role of SP-D during C. neoformans (strain H99, serotype A) infection using SP-D Ϫ/Ϫ and triple-transgenic inducible SP-D Ϫ/Ϫ mouse strains. Fungal burden and mouse survival were assessed, and in vitro assays were employed to examine the ability of SP-D to modulate C. neoformans growth in response to oxidative stress. We found that the presence of SP-D enhances the survival and proliferation of C. neoformans cells in vivo, as evidenced by the observation that SP-D Ϫ/Ϫ mice have decreased fungal burden and are partially protected during C. neoformans infection. Furthermore, AMs isolated from SP-D Ϫ/Ϫ mice demonstrated a greater ability to kill C. neoformans cells than did wild-type AMs, and preopsonization of the yeast cells with SP-D protected them against oxidative stress, an effect similar to that observed previously for the capsule on yeast cells (63) , both in vitro and in vivo. Thus, we conclude that SP-D protects C. neoformans cells against host innate immune responses, in particular the activity of oxidants, and that this fungal protection is sufficient to partially overcome the enhanced antifungal activity of SP-D Ϫ/Ϫ murine macrophages, which may be related their enhanced oxidant production (62) . These data suggest that C. neoformans cells have evolved a mechanism to subvert host innate immune defenses via the exploitation of host SP-D, a finding that could impact targeting strategies used to identify and manage patients presenting with cryptococcosis.
MATERIALS AND METHODS

Animals and reagents.
Experiments were conducted using pathogen-free C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME); SP-D Ϫ/Ϫ mice on the C57BL/6 background, as previously described (31); triple-transgenic [CCSP-rtTA (tetO)7-rSP-D SP-D Ϫ/Ϫ ] inducible SP-D Ϫ/Ϫ mice, kindly provided by Jeffrey Whitsett (66) (designated plusdoxySP-D ϩ/ϩ and offdoxySP-D Ϫ/Ϫ when fed doxycycline or not, respectively); and FVB/N controls for the triple-transgenic mice (Taconic, Hudson River Valley, NY). Inducible mice were raised on chow supplemented with 0.0625% doxycycline (625 ppm) to induce SP-D expression. Two weeks prior to infection with C. neoformans, half of the mice were switched to a diet of standard chow lacking doxycycline to obtain offdoxySP-D Ϫ/Ϫ mice, and the absence of SP-D in the lungs was validated by Western blot analysis of the bronchoalveolar lavage (BAL) fluid, which was tested following centrifugation to remove cells and cellular debris. All chow was provided ad libitum. For all experiments, the mice were age-and sex-matched and ranged between 8 and 10 weeks of age. Animals were anesthetized via intraperitoneal injection of ketamine (150 mg/kg of body weight) and xylazine (10 mg/kg) and euthanized by intraperitoneal injection of pentobarbital sodium (Nembutal; Abbot Laboratories, North Chicago, IL), followed by exsanguination. For isoflurane anesthesia, each mouse was exposed to isoflurane via inhalation in a closed container containing a Styrofoam platform atop gauze soaked in isoflurane. Mice were immediately removed from the container when their heads fell and rested on the platform.
Isolation of recombinant SP-D. Recombinant SP-D was isolated from Chinese hamster ovary cells expressing a clone of full-length rat SP-D, purified using maltose affinity chromatography, and stored at 4°C in 5 mM Tris buffer (pH 7.8) containing 2 mM EDTA, as previously described (37) . Prior to the use of SP-D, EDTA was removed by dialysis against phosphate-buffered saline (PBS) lacking Ca 2ϩ and Mg 2ϩ , to avoid protein precipitation.
Isolation of alveolar macrophages. Mice were killed by intraperitoneal injection of pentobarbital sodium (Abbott Laboratories, North Chicago, IL), followed by exsanguination. The trachea was cannulated after a midline neck incision was made, and the lungs were lavaged five times with 1.0 ml of PBS solution containing EGTA (1 mM). The BAL fluid volume recovered from each mouse was documented for normalization purposes. The lavage fluid was centrifuged (600 ϫ g for 10 min at 4°C), and the cells were washed with PBS and resuspended in Dulbecco's modified Eagle's medium (DMEM) (BioWhittaker, Inc., Walkersville, MD) containing 10% heat-inactivated fetal bovine serum, glutamine (300 g/ ml), penicillin (100 U/ml), and 20 mM HEPES (pH 7.2).
Culture and maintenance of C. neoformans strains. Cells of C. neoformans serotype A wild-type strain H99 and the cap59⌬::HYG mutant, a mutant strain created from H99 (48), were maintained in glycerol stocks. Previously, we showed that SP-D increased the uptake of acapsular, avirulent cap59⌬::HYG cells by AMs and that the presence of capsule abrogated this effect. Consequently, H99 and cap59⌬::HYG cells were compared in the present in vivo study. Stocks of the respective strains were streaked out onto yeast extract-peptone-dextrose (YPD) agarose or YPD plus hygromycin agarose plates and incubated at 30°C. Liquid cultures were grown in YPD medium at 30°C for 16 to 18 h in a shaking incubator at 250 rpm.
Microscopy. For all microscopy, a Zeiss (Thornwood, NY) Axioskop 2 Plus fluorescence microscope with an attached AxioCam MRM digital camera was utilized. A fixed exposure was used for all images, and the results represent data from experiments that were performed at least three times.
Preparation of C. neoformans for macrophage killing assays. C. neoformans cells grown overnight in YPD liquid medium were collected by centrifugation at 2,000 ϫ g, washed three times, and resuspended in sterile phosphate-buffered saline containing 0.9 M CaCl 2 at a concentration of 2 ϫ 10 6 yeast cells/ml. Yeast cells were then incubated alone or with 1 g/ml SP-D for 1 h at 37°C with shaking in an Eppendorf 5436 Thermomixer (Eppendorf, Westbury, NY). For macrophage infection, 10 l of pretreated yeast cells (20,000 yeast cells) was inoculated into wells containing activated macrophages. This number of yeast cells was chosen to represent a multiplicity of infection (MOI) of 1:1, with the assumption that the macrophage numbers had doubled overnight.
Alveolar macrophage killing assays. Alveolar macrophages were counted with a hemocytometer using trypan blue to identify dead cells and were resuspended at a concentration of 1 ϫ 10 5 live cells/ml. One hundred microliters of this suspension (10,000 cells) was plated into a 96-well plate. Macrophages were allowed to adhere overnight, and the medium was subsequently replaced with 100 l fresh complete medium containing 100 ng/ml lipopolysaccharide (LPS) (serotype 0111:B4) and 200 U/ml mouse gamma interferon for 3 h to activate the cells. An additional 100 l of complete medium was then added to the cells, and C. neoformans cells pretreated with SP-D were added to the macrophages at an MOI of 1:1. Controls included wells containing macrophages alone and C. neoformans cells alone for each pretreatment condition. Killing was assessed after 16 h by removing the supernatant from each well and lysing the macrophages with 2 washes of 100 l 0.01% SDS in phosphate-buffered saline. The supernatant and SDS washes were combined for each condition, serially diluted, and plated onto YPD agarose plates for colony forming unit (CFU) analysis. The results were assessed by comparing the CFUs from each macrophage and C. neoformans condition to those of the respective C. neoformans-alone controls, as follows: (CFUs [macrophage ϩ C. neoformans]/CFUs [C. neoformans]) ϫ 100. The resultant values were plotted by setting the yeast-only controls to zero to clearly indicate positive and negatives changes in C. neoformans growth in response to the different experimental conditions. This strategy allowed us to normalize for distinct growth rates of different strains and any effects caused by SP-D preopsonization. Experiments were performed in replicates of five, and the results represent data obtained from at least three independent experiments.
Animal infections.
Mice anesthetized by intraperitoneal injection of ketamine (150 mg/kg) and xylazine (10 mg/kg) were positioned on a taut string secured at either end, hanging from their incisors. C. neoformans cells in sterile phosphate-buffered saline at 1 ϫ 10 6 yeast cells/ml or 2 ϫ 10 5 yeast cells/ml were delivered by dropping the inoculum into the nares. Mice treated in the same way with sterile saline and uninfected mice were included as controls. For the delivery of exogenous SP-D, the C. neoformans inoculum was supplemented with 1 g/ml (oxidative stress assays) or 2 g/ml (rescue survival) of SP-D, as indicated. Anesthetized mice were kept warm with a heating blanket and monitored until full recovery from the procedure was achieved.
Protein measurement. C. neoformans strain H99 or cap59⌬ cells were intranasally instilled in anesthetized wild-type and SP-D Ϫ/Ϫ mice at a concentration of 5 ϫ 10 4 cells/mouse. The mice were then euthanized at 12 h postinfection by a lethal injection of sodium pentobarbital followed by exsanguination. The lungs were lavaged using a 20-gauge cannula to inject phosphate-buffered saline containing 0.2 mM EGTA. The lungs were inflated to full capacity (approximately 1 ml of buffer), and the first 1 ml of lavage buffer was collected and stored at Ϫ80°C for later analysis of protein concentrations. The protein concentration in the BAL fluid was determined using the bicinchoninic acid (BCA) protein assay (Pierce), with known dilutions of bovine serum albumin as standards.
Histology. Wild-type and SP-D Ϫ/Ϫ mice infected with C. neoformans cells as described above were euthanized by a lethal dose of pentobarbital sodium followed by exsanguination. The lungs were then perfused with warm sterile phosphate-buffered saline and fixed by the intratracheal instillation of 4% paraformaldehyde under gravity flow (27) . The lungs were paraffin-embedded, sectioned at a thickness of 4 m, and stained with hematoxylin and eosin to visualize lung morphology, cell infiltration, and fungal burden.
CFU analyses. Wild-type and SP-D Ϫ/Ϫ mice infected with C. neoformans cells as described above were euthanized, and the lungs, spleens, and brains were harvested for CFU analyses at the indicated time points to determine fungal burden and dissemination. Whole organs were homogenized in 1 ml of sterile phosphate-buffered saline using a tissue homogenizer. Serial dilutions of the homogenized tissues were plated onto YPD agarose plates, and the colonies were counted following incubation at 30°C for 2 to 3 days.
Hydrogen peroxide assays. C. neoformans cells (H99 and cap59⌬) were collected by centrifugation, washed three times with phosphatebuffered saline, and incubated with 1 g/ml SP-A, 1 g/ml SP-D, or buffer alone as a control for 1 h at 37°C with shaking. The yeast cells were then centrifuged to remove unbound protein and adjusted to a concentration of 1 ϫ 10 6 yeast cells/ml in yeast nitrogen base (YNB) medium. The pretreated yeast cells were exposed to 1 mM hydrogen peroxide (H 2 O 2 ) for 2 h at 37°C with shaking, followed by dilution and plating onto YPD agarose plates for CFU evaluation as described above.
XTT assays. C. neoformans cells (H99 and cap59⌬) were pretreated and exposed to H 2 O 2 as described above for the H 2 O 2 assays. The samples were then plated onto a 96-well plate in triplicate, and XTT {sodium 3-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene sulfonic acid hydrate} reagent (Sigma-Aldrich, St. Louis, MO) together with the electron donor phenazine methosulfate (Sigma-Aldrich, St. Louis, MO) were added to each well as previously described (51) . This assay is based on a color change as the XXT reagent is metabolized by the organism under study to a formazan product, thus indicating the viability of the sample. Plates were evaluated with a plate reader at an absorbance wavelength of 450 nm to compare differences in cell metabolism under the different conditions. Survival studies. Mice were intranasally instilled with 5 ϫ 10 4 or 1 ϫ 10 4 yeast cells delivered in 50 l of sterile phosphate-buffered saline as described above. For the rescue survival studies, 50 l of exogenous SP-D at a concentration of 2 g/ml was delivered into the lungs on days 0, 1, 3, 5, 10, and 15 postinfection. SP-D administered on day 0 was delivered together with the infectious inoculum via intranasal instillation. All subsequent doses were delivered via intratracheal instillation under isoflurane anesthesia. Mice were monitored until they regained consciousness and then twice daily for signs of morbidity (weight loss equal to or greater than 15% of their original body weight, symptoms of central nervous system [CNS] infection, respiratory distress, and any other signs of illness), at which point they were euthanized by carbon dioxide inhalation followed by bilateral thoracotomy.
Statistics. The two-tailed Student t test was used for all comparisons between two groups. For comparisons of multiple groups, a one-way or two-way analysis of variance (ANOVA) followed by Tukey's multiplecomparison or Bonferroni's posttest, respectively, was employed. Survival analyses were conducted by a Kaplan-Meier survival curve analysis using the log-rank (Mantel-Cox) test. All statistical analyses were performed using Graphpad Prism, version 5.0, software. A P value of Ͻ0.05 was considered statistically significant.
RESULTS
SP-D
؊/؊ mice are protected during C. neoformans infection. To assess whether SP-D affects the overall disease outcome in C. neoformans-infected mice, age-and weight-matched SP-D Ϫ/Ϫ and wild-type-background control mice were intranasally instilled with 5 ϫ 10 4 C. neoformans cells, and survival studies were performed. The SP-D Ϫ/Ϫ mice displayed a significantly prolonged mean time to death compared to the wild-type mice, as assessed over 35 days (P Ͻ 0.0001) (Fig. 1A) . To confirm that this observation was not due solely to the heightened inflammatory state associated with the SP-D (Fig. 1C) . Of note, doxycycline has been observed to have no direct antifungal activity against H99 in vitro. As observed with the SP-D Ϫ/Ϫ mice, a significant delay in the mean time to death was documented for transgenic mice lacking SP-D (Fig. 1B) Ϫ/Ϫ and wild-type mice displayed comparable fungal burdens in the lung tissue at 3 days postinfection, as confirmed by histology, which revealed similar levels of disease progression in the lung tissues of both strains (Fig. 2) . Remarkably, a significantly decreased fungal burden was apparent in SP-D Ϫ/Ϫ BAL fluid 
FIG 2 SP-D
Ϫ/Ϫ mice display decreased fungal burden in the BAL fluid from the lungs, but not the lung tissue, 3 days after instillation of H99 cells (A) and decreased fungal burden in both compartments at 7 days postinstillation (B). The results for fungal burden in the BAL fluid are presented as CFU/ml of the collected BAL fluid, and those for fungal burden in the lung tissue are presented as CFU/g of collected lung tissue. Each experimental group contained at least 10 mice. Scale bar, 100 m. *, P ϭ 0.053; **, P Ͻ 0.01. compared to that in wild-type BAL fluid (P Ͻ 0.01) (Fig. 2A) . Furthermore, in comparison to saline-instilled control mice, SP-D Ϫ/Ϫ mice infected with H99 or cap59⌬ cells demonstrated increased protein levels in the BAL fluid at 12 h postinfection (data not shown). Because the alveolar compartment sampled by lavage represents an initial port of pathogen entry, these results suggest that SP-D plays an important role during initial infection by augmenting the survival and/or proliferation of C. neoformans cells, which may be critical for disease outcomes. In support of this hypothesis, at 7 days postinfection, SP-D Ϫ/Ϫ mice again displayed a decreased fungal burden in the BAL fluid (P ϭ 0.053) and a significantly diminished fungal burden in the lung tissue (P Ͻ 0.01), with considerably less infection apparent by lung histology than for wild-type mice (Fig. 2B) .
SP-D promotes C. neoformans growth in the lung and increases dissemination to the spleen and brain in vivo. To ascertain the time course of C. neoformans infection and dissemination, CFU analyses of the lungs, spleen, and brain were performed to compare wild-type and SP-D Ϫ/Ϫ mouse strains at various time points postinfection. Not only did the SP-D Ϫ/Ϫ mice display decreased fungal burdens compared to those of wild-type mice in all organs at all time points evaluated, they also revealed a delay in the dissemination of the fungus from the lungs to the spleen and brain; dissemination occurred between 10 and 12 days postinfection in wild-type mice versus 12 to 15 days in SP-D Ϫ/Ϫ mice (Fig.  3) . These studies were also performed using the triple-transgenic mouse strain, and similar results were obtained (data not shown). Of interest, experiments identical to the H99 studies were performed with the cap59⌬ mutant strain, which does not disseminate from the lungs, and the results revealed significantly increased fungal burdens in the lungs of wild-type compared to SP-D Ϫ/Ϫ mice. In fact, infection with this mutant strain appeared to be effectively cleared in the SP-D Ϫ/Ϫ mice by 80 days postinfection (Fig. 4) (Fig. 5 ).
SP-D protects C. neoformans cells against oxidative stress, and yeast cells recovered from infected SP-D
؊/؊ mice display a "leaky-capsule" morphology. To further assess the mechanism(s) of SP-D's pathogen-protective effect, we evaluated H 2 O 2 both in vitro and in vivo (Fig. 6A and B, respectively) . Wild-type yeast cells obtained from the BAL fluid of SP-D Ϫ/Ϫ mice at 3 days postinfection were more susceptible to oxidative insult than those (Fig. 6B) . We further noted that the capsules of C. neoformans cells incubated in the presence of SP-D were larger than those of C. neoformans cells incubated in the absence of SP-D (Fig. 7) , and therefore, we considered whether the protective effect of SP-D on yeast cells might be attributable to a facilitation of capsule enlargement, to SP-D itself, or, potentially, to both mechanisms.
SP-D is sufficient to protect C. neoformans cells against oxidative stress. To evaluate whether SP-D functions to reinforce and/or to physically stabilize the protective effect of the capsule or is sufficient alone to protect C. neoformans cells against oxidative stress, we utilized the acapsular cap59⌬ mutant and assessed yeast viability following exposure to 1 mM H 2 O 2 . The results were validated by using two techniques: CFU analysis and a sodium 3-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene sulfonic acid hydrate (XTT) assay. SP-D, but not SP-A, protected cap59⌬ cells against oxidative stress (Fig. 8) , which demonstrated that SP-D itself could shield this yeast against critical host-mediated defense mechanisms, even in the absence of capsule (P Ͻ 0.05 and P Ͻ 0.01). 
DISCUSSION
Surfactant proteins A and D have been found to play critical hostprotective roles in the lung during innate immune responses to infectious and allergenic materials (8, 9, 49) . Intriguingly, and in contrast to the host-protective prototype proposed for these proteins against invading pathogens, we found that SP-D in fact functions to facilitate infection with the pathogenic fungus C. neoformans by protecting the fungus against host-produced reactive oxygen species (ROS) and facilitating its dissemination from the lungs to the CNS. Consistent with our previous studies showing that SP-D is protective against macrophage-mediated defense mechanisms (17), we found here that SP-D shielded C. neoformans cells against H 2 O 2 -induced oxidative stress, a component of the immune cell respiratory burst, in vitro and on yeast cells recovered directly from the alveolar compartment. We further showed that in the presence of endogenous SP-D in wild-type mice, the progression of C. neoformans infection was facilitated, leading to greater fungal burdens in the lung, spleen, and brain and faster dissemination from the lungs to the CNS than in SP-D Ϫ/Ϫ mice. These findings support our hypothesis that, in contrast to its well-accepted host-protective roles, SP-D promotes the course of infection of C. neoformans cells and thus may function as a risk factor. SP-D has been found to facilitate the clearance of numerous bacterial, viral, and fungal pathogens via a number of different mechanisms, including aggregation, increased phagocytosis, and the elicitation of various cytokines/chemokines. The mechanisms of SP-D's host-protective role have been well enumerated in the context of bacteria and viruses (18, 22, 50) , yet its function during fungal infections is less well characterized, with the most comprehensive fungal studies being performed with Aspergillus fumigatus. The pathogenic fungus A. fumigatus can cause both hypersensitivity reactions and invasive disease, and SP-D has been shown to be host protective in both of these disease models, as evidenced by robust in vitro and in vivo studies (43, 44) . (6, 9, 17, 30, 34, 61) . Furthermore, AIDS patients, who are at a particularly high risk of developing opportunistic fungal pulmonary infections, have been shown to possess elevated levels of SP-D in their lungs (28) . Based on the present findings, we speculate that following yeast cell inhalation, increased levels of SP-D in the pulmonary space might participate in promoting C. neoformans infection. In the present study, we demonstrated that C. neoformans yeast cells subverted host pulmonary innate immune responses via SP-D bound to their surface for protection against oxidative stress, which has been shown to be an important host-protective mechanism during C. neoformans infection (2, 46, 63) . Ϫ/Ϫ and wild-type mice than that between offdoxySP-D Ϫ/Ϫ and plusdoxySP-D ϩ/ϩ mice. Alternatively, higher concentrations of SP-D and/or a more frequent dosing schedule than those utilized in the present study may be necessary to achieve a complete rescue of the SP-D Ϫ/Ϫ phenotype. To discriminate between the two hypotheses, survival experiments may be performed in inducible mice using different periods of doxycycline removal, as previous analyses have shown that the number of activated macrophages increases with time after doxycycline has been removed from the diet.
An ability to subvert the host-protective functions of SP-D has been reported previously for some fungal pathogens. A host-detrimental effect of SP-D was described for P. carinii, although in that study, mice overexpressing SP-D were compared to those expressing physiological levels of SP-D (61). In addition, SP-D has been shown to abrogate TNF1-␣ production by alveolar macrophages in response to B. dermatitidis infection (34), potentially facilitating disease progression. These findings suggest that some fungal pathogens are equipped to utilize the host-protective properties of SP-D to their advantage; however, further investigations using in vivo models of disease are needed to confirm this hypothesis, as disparities between in vitro and in vivo models are often encountered (17) . It is intriguing to speculate that the innate host immune functions of SP-D established for bacterial and viral infections are not generally applicable to certain fungal infections. One might postulate an evolutionary explanation for this observation; for example, eukaryotic fungal cells may possess a honed ability to recognize, respond to, and subvert host machinery compared with prokaryotic bacteria and viruses.
C. neoformans cells exploit a number of strategies to promote their survival in the host. We have previously shown that SP-D on the surface of C. neoformans cells functions as an opsonin by increasing their phagocytosis by macrophages. However, we have also observed that SP-D-bound fungi are in fact protected against macrophage-mediated defense mechanisms; they display increased survival compared with uncoated yeast cells. Other studies have shown that C. neoformans cells can survive intracellularly and then extrude from host immune cells via a process known as vomocytosis (3, 4, 38, 39, 41) . In support of these properties being beneficial to the fungus, a recent study employing a panel of C. gattii strains with various virulence patterns revealed that increased intracellular survival correlates directly with increased fungal virulence (40) . This finding is consistent with hypotheses that C. neoformans cells disseminate from the pulmonary space via intracellular parasitism and that the ability to survive intracellularly enables the fungus to evade host immune responses. From an evolutionary perspective, the ability of C. neoformans cells to survive in amoebae may have provided this fungus the opportunity to evolve robust intracellular survival strategies in nature (56) . In the present study, we provide further evidence that C. neoformans cells have evolved sophisticated tactics to promote their survival during infection by using host innate immune factors like SP-D.
Further studies should be aimed at confirming whether SP-D functions to subvert the innate immune response and enhance cryptococcal infection in humans, particularly in light of ongoing diagnoses of C. gattii infection in apparently immunocompetent individuals in the Pacific Northwest (7, 10-13, 29, 42) . Such studies might consider whether the various SP-D polymorphisms described in the literature (24, 32, 33, 35, 54) affect susceptibility to C. neoformans infection and/or C. gattii infection and, if so, whether genetic screening may facilitate infection risk stratification for prevention in individuals possessing other risk factors for cryptococcal disease. The present study provides evidence that SP-D is subverted by C. neoformans cells for increased uptake by immune cells and protection against oxidative stress, thus aiding disease progression. Further investigations in our laboratory are aimed at elucidating whether SP-D protects C. neoformans cells against oxidative stress by acting as a scavenger of highly reactive oxidant molecules or by upregulating the antioxidant capabilities of the yeast itself. Precedent for the latter is supported by recent studies demonstrating the capacity of mouse anticapsular antibodies to induce changes in the gene expression of C. neoformans cells (45) . Because the containment of infection during its early stages is critical for avoiding disease, the present findings elucidate important early host-pathogen interactions that could be targeted for clinical intervention, with the goal of both risk stratification and, ultimately, the development of a target(s) for a drug(s) or vaccine(s) to prevent infection and/or dissemination.
